Author + information
- Received December 13, 1985
- Revision received October 8, 1986
- Accepted November 3, 1986
- Published online June 1, 1987.
- ↵*Address for reprints: Walter H. Abelmann, MD, Cardiovascular Division, Beth Israel Hospital, 330 Brookline Avenue, Boston, Massachusetts 02215.
Effects of recombinant human leukocyte interferon α A/D on experimental myocarditis due to encephalomyocarditis virus were investigated. Plaque reduction assays revealed that 50% of plaque formation in vitro in human amnion (FL) cells was inhibited by interferon α A/D (9.7 U/ml) when it was administered 24 hours before infection with the encephalomyocarditis virus. Four week old male DBA/2 mice were inoculated intraperitoneally with 10 plaque-forming units (pfu) of encephalomyocarditis virus. Interferon α A/D was administered subcutaneously (102U/g body weight per day in Group 1, 103U/g per day in Group 2 and 104U/g per day in Group 3) starting 1 day before infection. It was also administered starting the same day in Group 4 and 1 day after virus inoculation in Group 5 (104U/g per day in both groups). Control mice were injected with saline solution. Each group consisted of 10 mice; they were killed on day 4 for evaluation.
Myocardial virus titers were significantly lower in Group 3 (8.2 ± 25.2 × 102pfu/mg, p < 0.05) and Group 4 (3.0 ± 5.5 × 103pfu/mg, p < 0.05) than in control mice (5.6 ± 4.1 × 104pfu/mg). Histologic examination showed extensive myocardial necrosis and cellular infiltration in all control mice, but no myocardial necrosis or cellular infiltration in Group 3 and less severe necrosis and infiltration in Group 4. There were no significant differences in myocardial virus titers or histologic changes between control mice and Group 1, 2 or 5.
Thus, interferon α A/D, when administered starting before or simultaneously with virus inoculation, effectively inhibited myocardial virus replication and reduced the inflammatory response and myocardial damage in an experimental model of viral myocarditis.
- Received December 13, 1985.
- Revision received October 8, 1986.
- Accepted November 3, 1986.
- American College of Cardiology Foundation